These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 36417488)

  • 81. Fragment length profiles of cancer mutations enhance detection of circulating tumor DNA in patients with early-stage hepatocellular carcinoma.
    Nguyen VC; Nguyen TH; Phan TH; Tran TT; Pham TTT; Ho TD; Nguyen HHT; Duong ML; Nguyen CM; Nguyen QB; Bach HT; Kim VV; Pham TA; Nguyen BT; Nguyen TNV; Huynh LAK; Tran VU; Tran TTT; Nguyen TD; Phu DTB; Phan BHH; Nguyen QT; Truong DK; Do TT; Nguyen HN; Phan MD; Giang H; Tran LS
    BMC Cancer; 2023 Mar; 23(1):233. PubMed ID: 36915069
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Detection and monitoring of HBV-related hepatocellular carcinoma from plasma cfDNA fragmentation profiles.
    Sun X; Feng W; Cui P; Ruan R; Ma W; Han Z; Sun J; Pan Y; Zhu J; Zhong X; Li J; Ma M; Hu R; Lv M; Huang Q; Zhang W; Feng M; Zhuang X; Huang B; Zhou X
    Genomics; 2022 Nov; 114(6):110502. PubMed ID: 36220554
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Methylation-sensitive high-resolution melting analysis of the USP44 promoter can detect early-stage hepatocellular carcinoma in blood samples.
    Kim SC; Kim J; Kim DW; Choi Y; Park K; Cho EJ; Yu SJ; Kim-Ha J; Kim YJ
    BMB Rep; 2022 Nov; 55(11):553-558. PubMed ID: 36016503
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Cell-Free Virus-Host Chimera DNA From Hepatitis B Virus Integration Sites as a Circulating Biomarker of Hepatocellular Cancer.
    Li CL; Ho MC; Lin YY; Tzeng ST; Chen YJ; Pai HY; Wang YC; Chen CL; Lee YH; Chen DS; Yeh SH; Chen PJ
    Hepatology; 2020 Dec; 72(6):2063-2076. PubMed ID: 32171027
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Diagnostic Value of Circulating Free DNA Integrity and Global Methylation Status in Gall Bladder Carcinoma.
    Kumari S; Husain N; Agarwal A; Neyaz A; Gupta S; Chaturvedi A; Lohani M; Sonkar AA
    Pathol Oncol Res; 2019 Jul; 25(3):925-936. PubMed ID: 29376201
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Integrative analysis of DNA methylation and gene expression identify a six epigenetic driver signature for predicting prognosis in hepatocellular carcinoma.
    Li GX; Ding ZY; Wang YW; Liu TT; Chen WX; Wu JJ; Xu WQ; Zhu P; Zhang BX
    J Cell Physiol; 2019 Jul; 234(7):11942-11950. PubMed ID: 30536816
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Emerging role of circulating cell-free RNA as a non-invasive biomarker for hepatocellular carcinoma.
    Shetti D; Mallela VR; Ye W; Sharif M; Ambrozkiewicz F; Trailin A; Liška V; Hemminki K
    Crit Rev Oncol Hematol; 2024 Aug; 200():104391. PubMed ID: 38795877
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Methylome profiling identifies TCHH methylation in CfDNA as a noninvasive marker of liver metastasis in colorectal cancer.
    Chen S; Liu T; Bu D; Zhu J; Wang X; Pan Y; Liu Y; Lu ZJ; Wang P
    FASEB J; 2021 Jul; 35(7):e21720. PubMed ID: 34110642
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Genetic biomarkers for hepatocellular cancer risk in a caucasian population.
    De Mattia E; Cecchin E; Polesel J; Bignucolo A; Roncato R; Lupo F; Crovatto M; Buonadonna A; Tiribelli C; Toffoli G
    World J Gastroenterol; 2017 Sep; 23(36):6674-6684. PubMed ID: 29085212
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Gene body hypomethylation of pyroptosis-related genes NLRP7, NLRP2, and NLRP3 facilitate non-invasive surveillance of hepatocellular carcinoma.
    Zhang H; Dong P; Fan H; Liang H; Zhang K; Zhao Y; Guo S; Schrodi SJ; Fan Y; Zhang D
    Funct Integr Genomics; 2023 Jun; 23(2):198. PubMed ID: 37273114
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Targeted deep DNA methylation analysis of circulating cell-free DNA in plasma using massively parallel semiconductor sequencing.
    Vaca-Paniagua F; Oliver J; Nogueira da Costa A; Merle P; McKay J; Herceg Z; Holmila R
    Epigenomics; 2015; 7(3):353-62. PubMed ID: 26077425
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Plasma cfDNA methylation markers for the detection and prognosis of ovarian cancer.
    Liang L; Zhang Y; Li C; Liao Y; Wang G; Xu J; Li Y; Yuan G; Sun Y; Zhang R; Li X; Nian W; Zhao J; Zhang Y; Zhu X; Wen X; Cai S; Li N; Wu L
    EBioMedicine; 2022 Sep; 83():104222. PubMed ID: 35973389
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Methylation status of the T-cadherin gene promotor in peripheral blood mononuclear cells is associated with HBV-related hepatocellular carcinoma progression.
    Yuan XD; Wang JW; Fang Y; Qian Y; Gao S; Fan YC; Wang K
    Pathol Res Pract; 2020 May; 216(5):152914. PubMed ID: 32147273
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Identification of tumor mutations in plasma based on mutation variant frequency change (MVFC).
    Chen G; Peng F; Dong X; Cai Z; Li Z; He L; Hu J; Deng X; Guo Y; Qiu L; Zhou Y; Liu J; Zhang H; Liu X
    Mol Oncol; 2023 Sep; 17(9):1871-1883. PubMed ID: 37496285
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer.
    Barault L; Amatu A; Siravegna G; Ponzetti A; Moran S; Cassingena A; Mussolin B; Falcomatà C; Binder AM; Cristiano C; Oddo D; Guarrera S; Cancelliere C; Bustreo S; Bencardino K; Maden S; Vanzati A; Zavattari P; Matullo G; Truini M; Grady WM; Racca P; Michels KB; Siena S; Esteller M; Bardelli A; Sartore-Bianchi A; Di Nicolantonio F
    Gut; 2018 Nov; 67(11):1995-2005. PubMed ID: 28982739
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Discovery and validation of DNA hypomethylation biomarkers for liver cancer using HRM-specific probes.
    Stefanska B; Bouzelmat A; Huang J; Suderman M; Hallett M; Han ZG; Al-Mahtab M; Akbar SM; Khan WA; Raqib R; Szyf M
    PLoS One; 2013; 8(8):e68439. PubMed ID: 23950870
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma.
    Huang A; Zhao X; Yang XR; Li FQ; Zhou XL; Wu K; Zhang X; Sun QM; Cao Y; Zhu HM; Wang XD; Yang HM; Wang J; Tang ZY; Hou Y; Fan J; Zhou J
    J Hepatol; 2017 Aug; 67(2):293-301. PubMed ID: 28323123
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Targeted Next-Generation Sequencing Combined With Circulating-Free DNA Deciphers Spatial Heterogeneity of Resected Multifocal Hepatocellular Carcinoma.
    Lin J; Zhao S; Wang D; Song Y; Che Y; Yang X; Mao J; Xie F; Long J; Bai Y; Yang X; Zhang L; Bian J; Lu X; Sang X; Pan J; Wang K; Zhao H
    Front Immunol; 2021; 12():673248. PubMed ID: 34211467
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Unintrusive multi-cancer detection by circulating cell-free DNA methylation sequencing (THUNDER): development and independent validation studies.
    Gao Q; Lin YP; Li BS; Wang GQ; Dong LQ; Shen BY; Lou WH; Wu WC; Ge D; Zhu QL; Xu Y; Xu JM; Chang WJ; Lan P; Zhou PH; He MJ; Qiao GB; Chuai SK; Zang RY; Shi TY; Tan LJ; Yin J; Zeng Q; Su XF; Wang ZD; Zhao XQ; Nian WQ; Zhang S; Zhou J; Cai SL; Zhang ZH; Fan J
    Ann Oncol; 2023 May; 34(5):486-495. PubMed ID: 36849097
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Detection of a novel panel of somatic mutations in plasma cell-free DNA and its diagnostic value in hepatocellular carcinoma.
    Xiong Y; Xie CR; Zhang S; Chen J; Yin ZY
    Cancer Manag Res; 2019; 11():5745-5756. PubMed ID: 31303788
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.